---
canonical_name: Microdosing LSD Analogues
alternate_names: Microdosing 1P-LSD, Microdosing 1cP-LSD, Microdosing 1V-LSD, Microdosing ALD-52, 1-Acyl LSD Prodrug Microdosing, Lysergamide Microdosing, Microdosing LSD Research Chemicals
canonical_topic: Microdosing LSD Analogues for Health & Longevity
short_topic_lc: microdosing_lsd_analogues
creation_date: 2026-0705-1000
creator_ai_fullname: Opus 4.8
ep_keywords: Psychedelics, Serotonergic Psychedelics, Lysergamides, 5-HT2A Agonists, Prodrug Psychedelics
---

# Microdosing LSD Analogues for Health & Longevity
<section id="top" markdown="1"></section>

Evidence Review created on 06/30/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8

**Also known as:** Microdosing 1P-LSD, Microdosing 1cP-LSD, Microdosing 1V-LSD, Microdosing ALD-52, 1-Acyl LSD Prodrug Microdosing, Lysergamide Microdosing, Microdosing LSD Research Chemicals


## Motivation

<!-- This motivation section was written only after the rest of the document was completed, so that it accurately reflects the full scope of the review. -->

LSD analogues are chemically modified versions of lysergic acid diethylamide — compounds such as 1P-LSD, 1cP-LSD, 1V-LSD, and ALD-52 — that carry a small chemical add-on at one position on the LSD molecule. In the body, that add-on is cleaved off and the analogue is converted back into ordinary LSD, so it behaves as a "prodrug" (an inactive form that turns into the active drug after it is taken). These analogues emerged largely because they occupied a legal grey area that LSD itself does not, and they are sold as unregulated research chemicals. Microdosing means taking a very small, sub-perceptual amount — roughly a tenth of a recreational dose — on a repeating schedule, with the goal of subtle mood, focus, or creativity effects rather than a noticeable altered state.

Interest exploded over the past decade as people sought a legally accessible route to the mood and cognitive claims attached to LSD microdosing, and survey data suggest analogues are now a common real-world source of microdoses.

This review examines what is actually known about microdosing LSD analogues: how they work, what controlled and observational research shows about benefits and risks, and where the evidence is strong, weak, or absent.


**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**


## Recommended Reading

This section lists high-level, broadly accessible resources that introduce LSD analogues and the practice of psychedelic microdosing.

<!-- A real-time web search was performed for high-level overview content on LSD analogues and microdosing across expert platforms (Huberman Lab, Peter Attia, FoundMyFitness, Chris Kresser, Life Extension) and the general web. The 1-acyl lysergamide analogues are an unregulated research-chemical niche, so dedicated expert content on the analogues specifically is sparse; the items below cover the analogue pharmacology directly and the microdosing practice that applies to them, since the analogues convert to LSD in the body. No item from the same source is duplicated. -->

* [The Science of Psychedelics for Mental Health (Dr. Robin Carhart-Harris)](https://www.hubermanlab.com/episode/dr-robin-carhart-harris-the-science-of-psychedelics-for-mental-health) - Andrew Huberman

A long-form podcast episode with a leading psychedelic neuroscientist covering how classic psychedelics like LSD act on the brain, including a direct discussion of microdosing and the gap between popular claims and controlled data.

* [#182 – David Nutt: Psychedelics & Recreational Drugs](https://peterattiamd.com/davidnutt/) - Peter Attia

An interview with neuropsychopharmacologist David Nutt that situates LSD within drug-harm and regulatory frameworks, useful context for why analogues exist and how their legal status shapes access and safety.

* [Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD)](https://pubmed.ncbi.nlm.nih.gov/31756337/) - Halberstadt et al., 2020

The primary pharmacology paper demonstrating that ALD-52, 1P-LSD, and 1B-LSD are rapidly deacylated to LSD in vivo, establishing the prodrug mechanism that defines the entire analogue class.

* [Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration](https://pubmed.ncbi.nlm.nih.gov/32415750/) - Grumann et al., 2020

The first human pharmacokinetic data on an LSD analogue, showing that oral 1P-LSD is essentially fully converted to LSD with near-100% bioavailability and produces an LSD-like subjective profile.

* [Biohacking Your Ancestral Lifestyle, with Ben Greenfield](https://chriskresser.com/biohacking-your-ancestral-lifestyle-with-ben-greenfield/) - Chris Kresser

A Revolution Health Radio episode in which Chris Kresser and Ben Greenfield discuss LSD microdosing and name the analogue 1P-LSD directly, framing how the analogues are used and their legal and practical status from a functional-health perspective.

*Note: Among the priority experts, Andrew Huberman and Peter Attia provide directly relevant LSD-pharmacology and microdosing content, and Chris Kresser's Revolution Health Radio discussion names the analogue 1P-LSD in a microdosing context. Dedicated overview content on the 1-acyl lysergamide analogues specifically could not be found from Rhonda Patrick or Life Extension — their psychedelic coverage centers on psilocybin and general psychedelic therapy rather than these analogues — so the remaining slots are completed with the primary analogue-pharmacology papers.*


## Grokipedia

<!-- grokipedia.com was searched directly using the browser tool for "1cP-LSD"; the search returned 69 results including dedicated pages for 1cP-LSD, 1P-LSD, 1V-LSD, ALD-52-adjacent analogues, and LSD itself. The dedicated 1cP-LSD page is used as the primary entry for the analogue class. -->

[1cP-LSD](https://grokipedia.com/page/1cP-LSD)

A dedicated encyclopedia-style page on the representative analogue 1cP-LSD, covering its chemistry, prodrug conversion to LSD, dosing in blotter form, and regulatory history as a legal LSD alternative.


## Examine

<!-- examine.com was searched directly using the browser tool for "1cP-LSD"; the site returned "Sorry, there are no search results for 1cP-LSD." A broader check for "LSD" likewise returns no supplement monograph, consistent with Examine's scope being dietary supplements and nutrition rather than controlled drugs or research chemicals. -->

No Examine article exists for LSD analogues. Examine.com covers dietary supplements, vitamins, and nutrition compounds and does not maintain monographs on controlled psychedelics or unregulated research chemicals such as the 1-acyl lysergamides.


## ConsumerLab

<!-- consumerlab.com was searched directly using the browser tool for "1cP-LSD" and for "LSD"; the site is protected by an anti-bot challenge that blocks automated search, but ConsumerLab's editorial scope is the independent laboratory testing of vitamins, minerals, herbal, and dietary supplement products, which does not include controlled psychedelics or research chemicals. -->

No ConsumerLab article exists for LSD analogues. ConsumerLab independently tests dietary supplements and nutrition products for purity and label accuracy and does not cover controlled psychedelics or unregulated research chemicals such as the 1-acyl lysergamides.


## Systematic Reviews

The following systematic reviews and meta-analyses address low-dose (microdose) classic psychedelics, principally LSD and psilocybin; because LSD analogues convert to LSD in the body, the LSD findings apply directly to the analogue class.

* [Effects of psychedelic microdosing on cognitive functions: A systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/41314362/) - Pinhas et al., 2026

A preregistered meta-analysis of 14 controlled studies (N = 1614) finding a small but significant decrease in cognitive control with microdosing and no detectable benefit in other cognitive domains.

* [Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis](https://pubmed.ncbi.nlm.nih.gov/42365488/) - Özaydın & Canlan Özaydın, 2026

An umbrella review concluding that placebo-controlled mood benefits are not replicated and that the only consistent controlled cognitive finding is a small impairment, while flagging uncharacterized cardiovascular and 5-HT₂B (a heart-valve serotonin receptor) risks.

* [Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes](https://pubmed.ncbi.nlm.nih.gov/40058407/) - Modzelewski et al., 2025

A systematic review of 31 studies characterizing microdose side effects as typically dose-dependent, mild, and short-lived, most commonly increased blood pressure, anxiety, and cognitive impairment.

* [The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field](https://pubmed.ncbi.nlm.nih.gov/35609684/) - Polito & Liknaitzky, 2022

A broad synthesis of 44 studies spanning pre-prohibition and modern research, proposing standardized dose ranges and arguing that expectancy alone cannot fully explain reported effects.

* [Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review](https://pubmed.ncbi.nlm.nih.gov/33031815/) - Ona & Bouso, 2020

An early systematic review documenting highly contradictory efficacy results and emphasizing the strong role of the placebo effect and methodological limitations in the microdosing literature.


## Mechanism of Action

LSD analogues are "prodrugs": each is the LSD molecule with a small chemical group attached to the indole nitrogen (the N1 position). On their own these added groups sharply reduce binding to the brain's serotonin receptors — by roughly one to two orders of magnitude at the 5-HT₂A receptor (a serotonin "type 2A" docking site that is the main trigger for psychedelic effects). The intact analogues are therefore weak partial agonists or near-inactive at that site. What makes them work is chemical cleavage in the body: enzymes and spontaneous hydrolysis (a water-driven splitting reaction) remove the added group, regenerating ordinary LSD, which is the true active agent.

Once converted, the pharmacology is LSD's. LSD is a potent partial agonist at the 5-HT₂A receptor; activation of this receptor on cortical pyramidal neurons increases glutamate signaling and is necessary for the characteristic psychedelic state. At microdoses, 5-HT₂A occupancy is low (in the single-digit percent range at ~10–20 µg LSD-equivalent), which is why no overt psychedelic experience occurs. The proposed microdose mechanism is subtle modulation of 5-HT₂A-linked cortical excitability and downstream networks rather than the large-scale connectivity changes seen at full doses. LSD also binds dopamine and other serotonin receptors, but 5-HT₂A is central.

A competing mechanistic view holds that the sub-perceptual effects attributed to microdosing reflect expectancy rather than direct receptor pharmacology. Controlled studies show that 5-HT₂A occupancy at microdose levels is minimal and that blinded participants often cannot distinguish microdose from placebo, so some researchers argue the proposed cortical mechanism may be too weak to produce the claimed mood and cognitive effects. Both views remain under active investigation.

Key pharmacological properties (of the regenerated LSD): elimination half-life approximately 3–6 hours; oral bioavailability of LSD from analogues approaching 100% (demonstrated for 1P-LSD); high lipophilicity with wide tissue distribution; metabolism primarily hepatic, with oxidative pathways and contributions from cytochrome P450 enzymes (a family of liver enzymes that break down drugs) including CYP2D6, CYP1A2, CYP2B6, and CYP2C9. The added acyl group itself is removed mainly by hydrolysis (by serum and tissue esterases) before the LSD core is metabolized.


## Historical Context & Evolution

LSD was first synthesized by Albert Hofmann at Sandoz in 1938 and its psychoactivity discovered in 1943; it was investigated extensively as a psychiatric tool in the 1950s and 1960s before prohibition halted research. ALD-52 (1-acetyl-LSD) dates to this early era and was studied as an LSD-like compound of comparable potency. The deliberate creation of 1-acyl LSD analogues as consumer products, however, is a 21st-century development driven less by therapeutic ambition than by drug law.

The reason these analogues came to be considered at all is regulatory rather than scientific. Because LSD is tightly controlled almost everywhere, chemists produced N1-acylated derivatives — 1P-LSD (2015), 1B-LSD, 1cP-LSD, then 1V-LSD and others — each a molecule not explicitly named in existing drug schedules, sold openly as "research chemicals." As each analogue was scheduled in a given country, a new homolog appeared to replace it: 1V-LSD, for instance, emerged on the online market around 2021 specifically following restrictions on 1cP-LSD. This cat-and-mouse pattern, not a clinical rationale, explains the proliferation of the class. Their adoption for microdosing followed the broader microdosing trend popularized in the 2010s, with analogues offering a legally accessible supply.

The historical findings themselves are well described and not in dispute: laboratory work (in vitro serum incubation, rodent head-twitch assays, and limited human self-administration) consistently shows these compounds are hydrolyzed to LSD and reproduce LSD's behavioral and subjective profile. What has changed over time is the recognition that the analogues are best understood as LSD delivery systems rather than novel drugs in their own right. Scientific opinion is still evolving: the prodrug conversion is established, but the long-term safety, the reality of microdose benefits, and the regulatory standing of each analogue remain open and actively contested questions rather than settled matters.


## Expected Benefits

A dedicated search of clinical and expert sources (PubMed systematic reviews and meta-analyses, controlled LSD microdose trials, and microdosing survey literature) was performed before writing this section. Because LSD analogues convert to LSD, the benefit profile is that of LSD microdosing.

### High 🟩 🟩 🟩

No benefits of microdosing LSD analogues meet a High evidence grade. Controlled, placebo-blinded research has not established any reliable benefit at the High level; the strongest controlled signals are either null or run counter to popular claims.

### Medium 🟩 🟩

#### Acute, short-lived mood elevation on dosing days

In controlled and semi-controlled settings, microdoses of LSD are associated with modest, transient increases in self-reported positive mood states (feeling happier, more creative, more energetic) on the days a dose is taken, without improvement persisting between doses. An 8-week open-label Phase 2a trial in major depressive disorder found increased mood-related visual-analogue scores on dosing days but no significant change in core depression severity, and survey cohorts report similar acute uplift. The effect is small, on-drug, and confounded by expectancy.

**Magnitude:** Small acute increases in positive-mood visual-analogue scales on dosing days (p ≈ 0.009–0.039 in trial data); no durable between-dose mood change.

### Low 🟩

#### Self-reported wellbeing, focus, and creativity in observational cohorts

Large self-report and naturalistic studies — many of which include analogue users as a real-world microdose source — report perceived improvements in wellbeing, attention, and creativity. These outcomes are consistent across surveys but are not confirmed under blinding, and the most rigorous placebo-controlled work attributes much of the signal to expectancy. The evidence is abundant but low in quality and vulnerable to selection and placebo bias.

**Magnitude:** Improvements reported by a majority of users in uncontrolled surveys; effect sizes shrink to non-significant under placebo-controlled conditions.

#### Reduced symptoms in anxiety and depression (uncontrolled and early signals)

Open-label and observational data, plus a single-dose veterinary anxiety case series with the analogue 1cP-LSD, suggest possible anxiolytic and antidepressant signals at low doses. A human depression trial reported a mean 60% symptom reduction, but this was open-label and uncontrolled, so the result cannot be separated from placebo and natural course. The signal is preliminary and not replicated under blinding.

**Magnitude:** Up to ~60% self-reported depression symptom reduction in an open-label trial (uncontrolled); anxiety reduction observed in animal case reports.

### Speculative 🟨

#### Enhanced neuroplasticity and long-term cognitive or longevity benefit

It is hypothesized that repeated low-level 5-HT₂A activation could promote neuroplasticity (the brain's capacity to form new connections) and confer durable cognitive or brain-aging benefits relevant to longevity-focused users. This rests on full-dose psychedelic and animal mechanistic data, not on microdose evidence; a human microdose pharmacokinetic study specifically found no change in peripheral BDNF (a neuroplasticity marker), undercutting the simplest version of this claim. The basis is mechanistic and anecdotal only.

#### Cognitive enhancement (focus, problem-solving)

A central popular claim is that microdosing sharpens cognition. This is speculative and, where tested, contradicted: the best controlled meta-analytic evidence shows no cognitive enhancement and instead a small impairment of cognitive control. Any positive cognitive effect rests on uncontrolled self-report rather than experimental data.


## Benefit-Modifying Factors

The following factors may influence whether, and how strongly, an individual experiences any benefit from microdosing LSD analogues.

* **Cytochrome P450 genetics:** Variants in drug-metabolizing enzymes (notably CYP2D6, plus CYP1A2, CYP2B6, and CYP2C9) appear to influence LSD concentrations after a microdose; reduced-function metabolizers may achieve higher exposure from the same nominal dose, altering both effect and tolerability. In a microdose pharmacokinetic study, the two participants withdrawn for anxiety had intermediate-to-weak CYP2D6 activity.

* **Baseline mood and expectancy:** Reported benefit is strongly tied to baseline psychological state and to what the user expects. Individuals with low baseline mood and high positive expectancy report the largest gains, which is precisely the pattern expected of a placebo-sensitive outcome.

* **Sex-based differences:** Most controlled microdose and analogue-pharmacokinetic studies are heavily male (some exclusively so), so sex-specific benefit data are sparse. Body composition and hormonal differences could plausibly affect LSD distribution and response, but this is not well characterized for microdoses.

* **Pre-existing conditions:** A personal or family history of psychotic or bipolar spectrum disorders is expected to shift the risk-benefit balance unfavorably and may preclude benefit entirely; conversely, those with mild low mood are the group most likely to report subjective improvement.

* **Age:** The longevity-oriented target audience spans into older adulthood, where slower hepatic metabolism and greater cardiovascular sensitivity may raise LSD exposure and blunt the favorable tolerability seen in young-adult study samples. Microdose research is dominated by younger participants, so older-age benefit data are essentially absent.


## Potential Risks & Side Effects

A dedicated search of drug-reference and primary safety sources (systematic reviews of microdose side effects, LSD prescribing and pharmacology literature, and analogue-specific toxicology) was performed before writing this section. Risks reflect both the regenerated LSD and the unregulated nature of the analogue products.

### High 🟥 🟥 🟥

#### Product impurity, mislabeling, and dosing uncertainty (unregulated supply)

Because LSD analogues are sold as unregulated research chemicals, the actual identity, dose, and purity of a given blotter or pellet are not guaranteed. Analytical studies repeatedly find the lysergamide market populated by shifting, newly synthesized compounds, and forensic analyses have identified mixtures and substitutions in sheet products. A user cannot reliably know which analogue, at what dose, they are taking — the dominant practical risk of this class and distinct from pharmaceutical-grade LSD.

**Magnitude:** Dose per unit commonly 100–150 µg analogue (≈10–15 microdoses per blotter), so miscounting or uneven distribution can yield several-fold dosing errors; impurity rates are unquantified but structurally inherent to the market.

#### Acute cardiovascular and sympathetic effects

Even at microdoses, LSD produces measurable, dose-dependent increases in blood pressure and heart rate via serotonergic and sympathetic activation. Systematic reviews list raised blood pressure among the most common microdose side effects. For longevity-oriented users with hypertension or cardiovascular disease, repeated low-level pressor effects are a meaningful concern, and chronic 5-HT₂B receptor activation raises a theoretical valvulopathy risk with frequent long-term dosing.

**Magnitude:** Small but consistent increases in heart rate and blood pressure (heart-rate rise <15% above baseline at 10 µg LSD); long-term cardiac valve risk from repeated dosing is unquantified.

### Medium 🟥 🟥

#### Anxiety, jitteriness, and acute psychological discomfort

Anxiety is among the most frequently reported microdose side effects and is a leading reason participants withdraw from controlled studies. In a Phase 1 microdose LSD trial, four of eighty participants withdrew specifically due to anxiety. Effects are typically mild and short-lived but can be distressing, and an unexpectedly potent analogue or dose can convert an intended microdose into a perceptible, anxiety-provoking experience.

**Magnitude:** Anxiety reported in a substantial minority of users; ~5% withdrawal rate for anxiety in a controlled microdose trial.

#### Impaired cognitive control

Contrary to the enhancement claim, the most rigorous controlled evidence shows microdosing produces a small but reliable reduction in cognitive control — the capacity for focused, top-down regulation of attention and behavior. This is the single most consistent experimental finding in the microdosing literature and applies to LSD as the active species.

**Magnitude:** Pooled effect size approximately d = −0.34 (95% CI [confidence interval, the range the true effect likely falls within] −0.62 to −0.06) for reduced cognitive control across controlled studies.

### Low 🟥

#### Sleep disruption

Microdosers commonly report disturbed or lighter sleep, particularly when dosing later in the day, consistent with LSD's stimulating serotonergic action. The effect is generally mild and manageable by morning dosing, but it appears across self-report cohorts.

**Magnitude:** Reported by a minority of users; severity mild and largely tied to dose timing.

#### Headache, nausea, and transient physical complaints

Low-grade headache, nausea, gastrointestinal upset, and temperature dysregulation are reported sporadically at microdoses. They are typically transient and self-limiting but contribute to overall tolerability concerns.

**Magnitude:** Infrequent and mild; no quantified incidence specific to analogues.

### Speculative 🟨

#### Long-term and chronic-dosing harms

Because regular microdosing exposes users to repeated low doses over months, there are theoretical concerns about cumulative effects — chronic 5-HT₂B-mediated cardiac valve changes, unknown effects of chronic exposure to analogue-specific metabolites or impurities, and unstudied consequences of long-term sub-perceptual serotonergic stimulation. No controlled long-term safety data exist for any LSD analogue; the basis is mechanistic extrapolation and isolated reports.

#### Precipitation or worsening of psychosis in vulnerable individuals

In individuals predisposed to psychotic or bipolar spectrum illness, even low-dose serotonergic psychedelics are hypothesized to risk precipitating or worsening symptoms. Direct microdose evidence is lacking and the concern is extrapolated from full-dose psychedelic case reports, but the consequence would be severe, warranting caution.


## Risk-Modifying Factors

The following factors may raise or lower the risk and side-effect burden of microdosing LSD analogues.

* **Cytochrome P450 genetics:** Reduced-function CYP2D6 (and related CYP1A2/CYP2B6/CYP2C9) status can raise LSD exposure from a given microdose, increasing anxiety and cardiovascular side effects; the anxiety-related withdrawals in a microdose trial were in intermediate-to-weak CYP2D6 metabolizers.

* **Baseline blood pressure and cardiovascular status:** Pre-existing hypertension or cardiovascular disease amplifies the clinical significance of LSD's pressor effect and is the most important risk-elevating health factor, especially with repeated dosing and any 5-HT₂B-mediated valve concern.

* **Sex-based differences:** Safety data are derived overwhelmingly from male participants, so sex-specific risk (including any interaction with pregnancy, which is an absolute reason to avoid) is poorly characterized; the absence of data is itself a risk factor for women.

* **Pre-existing psychiatric conditions:** A personal or family history of psychosis, schizophrenia, or bipolar disorder is the key risk-elevating condition, theoretically raising the chance of precipitating serious psychiatric symptoms even at low doses.

* **Age:** Older adults within the longevity audience may have slower drug clearance and greater cardiovascular vulnerability, raising exposure and pressor risk relative to the young-adult samples that dominate the safety literature.


## Key Interactions & Contraindications

* **Serotonergic antidepressants (prescription):** SSRIs (selective serotonin reuptake inhibitors, e.g., fluoxetine, sertraline) and SNRIs (serotonin-norepinephrine reuptake inhibitors, e.g., venlafaxine) and especially MAOIs (monoamine oxidase inhibitors, e.g., phenelzine, tranylcypromine) interact with LSD. **Severity: caution to absolute contraindication.** Chronic SSRIs tend to blunt LSD effects, while MAOIs can unpredictably alter response; combining strong serotonergics raises a theoretical serotonin-excess concern. **Mitigation:** avoid combination, particularly with MAOIs.

* **Lithium:** **Severity: absolute contraindication.** Co-use of lithium with LSD is associated with reports of seizures and severe adverse reactions. **Mitigation:** do not combine.

* **Other prescription drugs affecting metabolism:** Strong CYP2D6 or CYP1A2 inhibitors (e.g., bupropion, fluvoxamine) can raise LSD exposure from an analogue dose. **Severity: caution.** **Mitigation:** account for higher effective exposure; consider lower dosing or avoid.

* **Over-the-counter medications:** Serotonergic OTC agents such as dextromethorphan (a cough suppressant) and St. John's Wort (a non-prescription herbal antidepressant) add serotonergic load. **Severity: caution.** **Consequence:** additive serotonergic effects. **Mitigation:** separate use or avoid.

* **Supplement interactions:** 5-HTP and L-tryptophan (serotonin precursors), SAMe, and other serotonergic supplements may add to serotonergic activity. **Severity: caution.** **Mitigation:** avoid concurrent serotonergic supplements.

* **Supplements with additive effects:** Serotonergic and stimulant supplements (5-HTP, L-tryptophan, high-dose caffeine, yohimbine) can additively increase anxiety, heart rate, and blood pressure when combined with an LSD-analogue microdose. These additive combinations should be specifically avoided.

* **Other intervention interactions:** Combining with other psychedelics or with recreational stimulants compounds cardiovascular and psychological risk and is discouraged.

* **Populations who should avoid this intervention:** Individuals with a personal or family history of psychotic or bipolar spectrum disorders; those with significant cardiovascular disease or uncontrolled hypertension; people taking lithium or MAOIs; and anyone who is pregnant or breastfeeding. **Specific thresholds:** uncontrolled hypertension (e.g., blood pressure ≥160/100 mmHg), any history of a psychotic episode, known cardiac valvulopathy, and pregnancy (any trimester) are clear reasons to avoid.


## Risk Mitigation Strategies

* **Verify product identity and dose where possible:** Because the unregulated supply carries a high risk of misidentification and mislabeling, using reagent or analytical testing to confirm the compound and estimating per-unit dose carefully directly mitigates the dominant risk of dosing uncertainty and impurity. Practically, this means treating a 100–150 µg blotter as ~10–15 microdoses and dividing it precisely rather than estimating.

* **Start at the lowest dose and titrate slowly:** Beginning at a true sub-perceptual amount (roughly 5–10 µg LSD-equivalent) and only adjusting upward after several doses mitigates the risk of an unexpectedly perceptible, anxiety-provoking experience from a more potent-than-expected analogue.

* **Dose in the morning:** Taking the microdose early in the day mitigates the sleep-disruption risk that follows from LSD's stimulating action, since the regenerated LSD has a half-life of only a few hours and clears before bedtime.

* **Screen for cardiovascular and psychiatric contraindications first:** Checking blood pressure and reviewing personal and family psychiatric history before starting mitigates the most serious risks — cardiovascular strain and precipitation of psychosis — by excluding those for whom the risk is highest.

* **Use intermittent, non-daily schedules:** Following a spaced schedule (for example dosing every third day rather than daily) limits cumulative exposure and mitigates the speculative chronic-dosing harms, including the theoretical 5-HT₂B valve concern, that would accompany continuous serotonergic stimulation.

* **Review concurrent medications and supplements:** Auditing for lithium, MAOIs, serotonergic drugs, and CYP-inhibiting agents before dosing mitigates the interaction risks of seizures, altered exposure, and additive serotonergic effects.


## Therapeutic Protocol

There is no clinically validated protocol for microdosing LSD analogues; the practices below are drawn from the microdosing community and from how the analogues are dosed in self-administration and emerging trial settings.

* **Standard practitioner-style protocol:** Most microdosing guidance derives from the popularized regimens of microdosing advocates (notably the schedules promoted by James Fadiman and the Third Wave organization), applied to analogues as an LSD-equivalent. A typical approach uses a sub-perceptual dose roughly one-tenth of a recreational dose, taken on a fixed intermittent schedule for a defined block of weeks.

* **Competing approaches without a default:** The two main schedules are the Fadiman protocol (one dose, then two days off, cycled over several weeks) and the Stamets-style or "every-other-day" patterns; controlled trials have instead used regular twice-weekly dosing. None is established as superior, and they are presented as alternatives rather than a standard.

* **Dose, in LSD-equivalent terms:** Because analogues convert to LSD, doses are expressed as LSD-equivalent, commonly 5–20 µg, with controlled trials titrating within roughly 6–20 µg. A 100 µg analogue blotter is typically divided into about ten microdoses.

* **Best time of day:** Morning dosing is standard, both to align any subtle alerting effect with the working day and to avoid sleep disruption given LSD's few-hour half-life.

* **Half-life consideration:** The active species, regenerated LSD, has an elimination half-life of approximately 3–6 hours, so a morning dose clears well before night; the analogue itself is hydrolyzed rapidly (often within the first hour for 1P-LSD).

* **Single versus split dosing:** Microdoses are taken as a single small dose per dosing day, not split, given the short duration and the goal of a brief sub-perceptual exposure.

* **Genetic considerations:** Pharmacogenetically, CYP2D6 (and related CYP1A2/CYP2B6/CYP2C9) status may warrant a lower starting dose in reduced-function metabolizers, who can reach higher LSD exposure from the same nominal amount.

* **Sex-based considerations:** Dosing data are derived largely from male participants; in the absence of sex-specific guidance, conservative starting doses are reasonable for women, with pregnancy an absolute reason not to use.

* **Age-related considerations:** Older adults may clear LSD more slowly and tolerate cardiovascular effects less well, so a lower starting dose and slower titration are prudent at the older end of the target range.

* **Baseline biomarkers:** Baseline blood pressure and heart rate are the most relevant pre-dosing measures; elevated readings argue for caution or avoidance.

* **Pre-existing conditions:** Pre-existing cardiovascular disease, hypertension, or psychiatric history (psychosis, bipolar disorder) should be addressed before any dosing and may contraindicate the protocol entirely.


## Discontinuation & Cycling

* **Intended duration:** Microdosing is generally practiced in defined blocks of several weeks rather than as a lifelong regimen; there is no evidence base supporting indefinite continuous use, and most popular protocols build in a planned end point.

* **Withdrawal effects:** No physical withdrawal syndrome is described for low-dose LSD; LSD is not associated with physical dependence, so discontinuation is not expected to produce withdrawal symptoms. Any rebound low mood after stopping is most plausibly loss of expectancy effect rather than pharmacological withdrawal.

* **Tapering:** Because no withdrawal occurs, a formal taper is not required; users typically simply stop at the end of a cycle.

* **Cycling for efficacy:** The intermittent, non-daily schedules central to microdosing are themselves a form of cycling, intended partly to avoid tolerance. LSD develops rapid tolerance with frequent full dosing, so spacing doses (e.g., every third day) and taking breaks between multi-week blocks is the standard way to maintain any effect and limit cumulative exposure.

* **Practical cycling pattern:** A common pattern is a 4–8 week dosing block followed by a break of several weeks before any further cycle, mirroring both popular protocols and the dosing windows used in trials.


## Sourcing and Quality

* **Unregulated, variable supply:** The defining sourcing problem is that LSD analogues are sold as research chemicals with no pharmaceutical quality control; identity, dose, and purity vary by vendor and batch, and the specific analogue on offer shifts as individual compounds are scheduled.

* **What to look for:** In the absence of regulated products, harm-reduction practice emphasizes reagent testing and, where available, quantitative analytical testing to confirm the compound's identity and dose; consistency of blotter manufacture and vendor transparency about the specific analogue are the only practical quality signals.

* **No reputable pharmaceutical or compounding source:** Unlike supplements or approved medications, there are no reputable brands or compounding pharmacies that legitimately supply these analogues for human use; pharmaceutical-grade LSD exists only within sanctioned clinical research, not consumer channels.

* **Legal and adulteration risk:** Sourcing carries legal risk that varies sharply by jurisdiction and the risk of receiving a different or adulterated compound than advertised, which compounds every downstream dosing and safety concern.


## Practical Considerations

* **Time to effect:** Any acute mood or alertness effect is felt the same day, within roughly 1–3 hours of a dose as the analogue converts to LSD; claimed cumulative benefits, where reported, are described over weeks of an intermittent schedule, though controlled data do not confirm durable effects.

* **Common pitfalls:** The most common mistakes are taking too high a dose (turning an intended microdose into a perceptible experience), assuming a blotter's labeled identity and dose are accurate, dosing too late in the day and disrupting sleep, and attributing all perceived benefit to the drug rather than to expectancy.

* **Regulatory status:** LSD itself is a Schedule I controlled substance in the United States and tightly controlled internationally. Analogues occupy a shifting grey area: many are unscheduled in some jurisdictions yet may be prosecutable as analogues (e.g., under the US Federal Analogue Act if intended for human consumption), and individual countries have progressively scheduled specific analogues, prompting new replacements. There is no approved medical use.

* **Cost and accessibility:** Analogues are relatively inexpensive and, where legally tolerated, easy to obtain online, which is much of their appeal; accessibility is highly jurisdiction-dependent and can change abruptly when a compound is scheduled.

* **Quality uncertainty:** As above, the practical experience is dominated by uncertainty about what is actually being taken, which colors every other consideration.


## Interaction with Foundational Habits

* **Sleep:** The interaction is direct and generally negative when timing is poor. LSD's stimulating serotonergic action can disrupt or lighten sleep, especially with afternoon or evening dosing; the practical mitigation is consistent morning dosing, after which the short half-life allows clearance before night.

* **Nutrition:** The interaction is largely indirect. There is no established dietary requirement, but concurrent serotonergic foods or supplements (e.g., heavy tryptophan or 5-HTP supplementation) could additively increase serotonergic load, and meals do not meaningfully change oral bioavailability, which is already near-complete.

* **Exercise:** The interaction is indirect and potentiating on the cardiovascular axis. Because microdoses modestly raise heart rate and blood pressure, combining a dose with intense exercise could additively elevate cardiovascular load; spacing vigorous training from dosing is a reasonable practical consideration, with no evidence that microdoses blunt or enhance training adaptations.

* **Stress management:** The interaction is direct but bidirectional. Subtle serotonergic modulation may improve subjective stress resilience for some users, but for anxiety-prone individuals a dose can heighten jitteriness and acute stress; pairing dosing with stress-management practices and avoiding it during high-anxiety periods is the practical approach.


## Monitoring Protocol & Defining Success

Before starting, baseline measurement focuses on cardiovascular and psychiatric safety rather than on a specific drug biomarker, since no validated efficacy biomarker for microdosing exists. Baseline testing should establish cardiovascular fitness for the pressor effects of LSD and screen for psychiatric contraindications.

Ongoing monitoring is primarily clinical and qualitative, with cardiovascular checks at sensible intervals: a blood-pressure and heart-rate check at baseline, again at roughly 1–2 weeks after starting a cycle, and periodically thereafter (every few weeks during a dosing block), plus reassessment before any subsequent cycle.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|---------------|
| Blood pressure | <120/80 mmHg | LSD raises blood pressure; identifies cardiovascular risk | Measure seated, rested; recheck on dosing days; conventional hypertension threshold is ≥130/80 mmHg |
| Resting heart rate | 50–70 bpm | LSD raises heart rate; flags sympathetic load | Best measured in the morning at rest, before dosing |
| Psychiatric history screen | No personal/family psychotic or bipolar history | Identifies those at risk of precipitated psychosis | Qualitative screen, not a lab; repeat if mental state changes |
| Lipid and metabolic panel (optional context) | Standard optimal ranges | General cardiovascular context for longevity users | Fasting; not specific to the drug but relevant to overall cardiovascular risk |

Qualitative markers are central to defining success here, since objective benefits are unproven. Users typically track these subjectively:

* Sleep quality and time to fall asleep (watching for disruption from dosing)
* Daytime mood and emotional stability
* Subjective focus, creativity, and motivation
* Anxiety or jitteriness levels on and off dosing days
* Overall sense of wellbeing across the dosing block

Success, realistically defined, is a clear and durable improvement in these qualitative markers that persists when honestly weighed against expectancy — alongside the absence of cardiovascular or psychological harm.


## Emerging Research

* **LSD microdosing for depression (Phase 2a, open-label):** An 8-week open-label trial of microdosed LSD in major depressive disorder reported a mean 60% symptom reduction with no tolerance or sensitization across repeated doses, though the uncontrolled design limits interpretation ([Daldegan-Bueno et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41713673/)). It provides early pharmacokinetic and mood data directly relevant to analogue users, since analogues convert to LSD.

* **Microdosing LSD in premenstrual disorders (planned trial):** A not-yet-recruiting trial plans to evaluate microdosed LSD for premenstrual syndrome and premenstrual dysphoric disorder in 150 women, addressing the major sex-data gap in the field ([NCT07189299](https://clinicaltrials.gov/study/NCT07189299)).

* **Serotonin-agonist mood and depression studies (early phase):** University of Chicago studies on the mood effects of serotonin agonists, including a recruiting early-phase depression study, are probing whether low-dose LSD effects exceed expectancy ([NCT07017478](https://clinicaltrials.gov/study/NCT07017478)).

* **Expectancy-controlled microdose design:** A recruiting study explicitly designed around expectancy aims to separate genuine pharmacological effects of low-dose LSD from placebo response ([NCT07061886](https://clinicaltrials.gov/study/NCT07061886)).

* **Analogue-specific pharmacology (could strengthen or refine the case):** Ongoing analytical and behavioral characterization of new lysergamide analogues continues to confirm the prodrug-to-LSD mechanism and could clarify analogue-specific differences in conversion and potency ([Brandt et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34837347/)).

* **Cognitive-control signal (could weaken the case):** Meta-analytic work showing impaired cognitive control with microdosing points to a research direction that, if confirmed, would undercut the central cognitive-enhancement claim ([Pinhas et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41314362/)).

* **Future research areas:** Adequately powered, preregistered, expectancy-controlled trials using verified analogue products are the key need; long-term cardiovascular (5-HT₂B valve) safety and sex-specific data are the most important gaps that could change current understanding.


## Conclusion

Microdosing LSD analogues means taking tiny, sub-perceptual amounts of chemically tweaked versions of LSD — such as 1P-LSD, 1cP-LSD, and 1V-LSD — that the body converts back into LSD itself. These compounds arose mainly to sidestep drug laws and are sold without quality control, so their defining feature for the user is uncertainty about what is actually being taken.

The hoped-for benefits center on better mood, focus, and creativity. The honest picture from careful research is sobering: blinded studies find that mood gains mostly disappear once expectation is accounted for, and the most reliable controlled finding is a small worsening of mental focus rather than the popular promise of sharper thinking. Reported real-world benefits are common but rest on weak, expectation-prone evidence.

On the other side sit modest but real downsides — raised blood pressure and heart rate, anxiety, disturbed sleep — plus the larger problems of an unregulated supply, legal risk that shifts by location, and serious unknowns about long-term and heart-valve safety. People with heart conditions or a personal or family history of serious mental illness face the greatest risk.

Overall, the evidence base is thin, short-term, and clouded by expectation. What these analogues do chemically is well understood; whether microdosing them helps is not.


**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**

<section id="iterations" markdown="1"></section>